Company Overview
Company Type: Public Company
Website: www.cardiolrx.com
Number of Employees: -
Ticker: CRDL (TSX)
Year Founded: 2017


Business Description
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
70.0
EBITDA
(36.2)
Total Enterprise Value
25.1
TEV/EBITDA
NM
EBIT
(36.4)
Cash & ST Invst.
44.9
P/Diluted EPS Before Extra
NM
Net Income
(30.0)
Total Debt
0.0
Price/Tang BV
1.8x
Capital Expenditure
(0.1)
Total Assets
47.2
Total Debt/EBITDA
NM




Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-05-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS (GAAP)
(0.11)
(0.09)
(0.42)
(0.38)
(0.39)
Revenue (mm)
0.00
0.00
0.00
0.00
0.00
EBITDA (mm)
-
-
(26.79)
(22.46)
(24.62)

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/EBITDA
NM
P/BV
1.47x

Non-Periodic Estimates

Recommendation
Buy (1.50)
Target Price
4.50
Potential Upside
281.36%


Key Professionals
Name
Title
Elsley, David G.
President, CEO & Director
Waddick, Christopher J.
CFO, Corporate Secretary & Director
Lim, Bernard 
Chief Operating Officer
Burns, Trevor 
Investor Relations
Hamer, Andrew Warwick
Chief Medical Officer & Head of Research & Development

Key Board Members
Name
Title
Torre-Amione, Guillermo 
Independent Chairman
Elsley, David G.
President, CEO & Director
Waddick, Christopher J.
CFO, Corporate Secretary & Director
Chao, Jennifer M.
Independent Director
Loxam, Teri 
Independent Director
Hill, Joseph A.
Member of Scientific Advisory Board
McManus, Bruce 
Member of Scientific Advisory Board
Pekos, Peter 
Independent Director
Ridker, Paul M.
Member of Scientific Advisory Board
Stott, Colin G.
Independent Director
Willner, Michael Jay
Independent Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
2265 Upper Middle Road East Suite 602 | Oakville, ON | L6H 0G5 | Canada

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 1.18
Market Cap (mm)
76.4
Open
 1.08
Shares Out. (mm)
64.8
Previous Close
 1.18
Float %
95.5%
Change on Day
0.10
Shares Sold Short (mm)
-
Change % on Day
9.3%
Dividend Yield %
-
Day High/Low
 1.18/ 1.07
Diluted EPS Excl. Extra Items
(0.47)
52 wk High/Low
 1.64/ 0.61
P/Diluted EPS Before Extra
NM
Volume (mm)
0.03
Avg 3M Dly Vlm (mm)
0.08
Beta 5Y
0.94


 
Delayed Quote** | Last Updated on Oct-06-2023 12:00 AM (GMT-5)
TSX:CRDL - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-9-2022
-
Public Offering
Target
Cardiol Therapeutics Inc. (TSX:CRDL)


50.00
Feb-8-2022
-
Shelf Registration
Target
Cardiol Therapeutics Inc. (TSX:CRDL)


14.92
Jan-25-2022
-
Shelf Registration
Target
Cardiol Therapeutics Inc. (TSX:CRDL)


150.00
Jan-18-2022
-
Shelf Registration
Target
Cardiol Therapeutics Inc. (TSX:CRDL)


8.94
Nov-2-2021
Nov-3-2021
Public Offering
Target
Cardiol Therapeutics Inc. (TSX:CRDL)


50.19
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-26-2023
Company Conference Presentations
Cardiol Therapeutics Inc. Presents at Cantor Fitzgerald Annual Global Healthcare Conference 2023, Sep-26-2023 04:55 PM
Sep-19-2023
Product-Related Announcements
Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in Archer, A Phase II Trial of Cardiolrx™ for the Treatment of Acute Myocarditis
Sep-11-2023
Company Conference Presentations
Cardiol Therapeutics Inc. Presents at H.C. Wainwright 25th Annual Global Investment Conference, Sep-11-2023
Aug-07-2023
Company Conference Presentations
Cardiol Therapeutics Inc. Presents at Canaccord Genuity 43rd Annual Growth Conference, Aug-07-2023
Jun-28-2023
Annual General Meeting
Cardiol Therapeutics Inc., Annual General Meeting, Jun 28, 2023


Advisors
Most Recent Auditor
BDO LLP
Private Placement Advisors
ATB Capital Markets Inc.
Public Offering Advisors
BDO Canada LLP, Borden Ladner Gervais LLP, Gowling WLG (Canada) LLP, Troutman Pepper Hamilton Sanders LLP


Most Recent Auditor
BDO LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 04:10 AM
CRDL
Cardiol Therapeutics Inc 2023_10_05
Reports
14
ValuEngine, Inc.

Oct 02, 2023 03:40 AM
CRDL
ValuEngine Rating and Forecast Report for CRDL
Reports
11
CFRA Equity Research

Oct 01, 2023 10:54 AM
CRDL
Cardiol Therapeutics Inc.
Reports
9
Leede Jones Gable Inc
Loe, Douglas W.
Sep 22, 2023 09:25 AM
CRDL
LJG: Healthcare & Biotechnology Weekly - September 22, 2023
Reports
9
Leede Jones Gable Inc
Loe, Douglas W.
Sep 19, 2023 03:44 PM
CRDL
LJG: Cardiol Therapeutics Inc. | CRDL-TSX - Update
Notes
6
GlobalData

Sep 13, 2023 02:15 AM
CRDL
Cardiol Therapeutics Inc (CRDL.TSE) - Financial Analysis Review
Reports
131
S&P Global Compustat

Sep 07, 2023 04:13 AM
CRDL
Cardiol Therapeutics Inc 2023_09_07
Reports
14
First Berlin Equity Research GmbH
Orquera, Christian
Aug 30, 2023 06:50 AM
CRDL
First Berlin: Cardiol Therapeutics Inc. - CARDIOLRX IN RP COULD SURPRISE POSITIVELY IN Q4 2023
Reports
10
GlobalData

Aug 18, 2023 04:48 AM
CRDL
Cardiol Therapeutics Inc (CRDL.NASD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
38
Canaccord Genuity
Nash, Edward Hamilton
Aug 15, 2023 02:26 PM
CRDL
Phase II data from recurrent pericarditis trial expected in 4Q23/1Q24 timeframe
EPS Estimates*
7


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


MM Asset Management Inc

2,953,300

4.56

3.2

Jun-30-2023


AXS Investments LLC

1,299,076

2.01

1.4

Jun-30-2023


AdvisorShares Investments, LLC

1,219,738

1.88

1.3

Jun-30-2023


Elsley MBA, David G.

1,154,500

1.78

1.3

May-12-2023


Willner Esq., Michael Jay

771,336

1.19

0.8

Sep-29-2023


Tejara Capital Limited., Asset Management Arm

497,061

0.77

0.5

Jun-30-2023


Pekos B.Sc., M.sc., Peter 

467,290

0.72

0.5

May-12-2023


BMO Asset Management Corp.

112,179

0.17

0.1

Jun-30-2023


Waddick C.A., C.M.A., CPA, CMA, MBA, Christopher J.

110,000

0.17

0.1

May-12-2023


Hamer M.D., Andrew Warwick

106,047

0.16

0.1

Feb-28-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
MGO One Seven LLC
100,000
100,000
Tejara Capital Limited., Asset Management Arm
497,061
56,435
AdvisorShares Investments, LLC
1,219,738
40,000
Cambridge Investment Research Advisors, Inc.
76,611
30,600
Loxam M.B.A., Teri 
60,000
30,000

Top Sellers
Sellers
Common Stock Equivalent Held
Change
AXS Investments LLC
1,299,076
(428,751)
MM Asset Management Inc
2,953,300
(200,100)
Susquehanna International Group, LLP, Asset Management Arm
36,613
(69,864)
Merrill Lynch & Co. Inc., Banking Investments
0
(60,000)
Robertson Stephens Wealth Management, LLC
0
(27,855)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
CardiolRx (Future), Cortalex, CRxIMT (Future)


Upcoming Events
Date/Time
Type
Oct-09-2023
Conferences
Oct-10-2023 3:00 PM (CET)
Company Conference Presentations
Nov-10-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-26-2023
-
Cardiol Therapeutics Inc. (TSX:CRDL)
SEDAR
News Releases
42 KB
Sep-26-2023
-
Cardiol Therapeutics Inc. (TSX:CRDL)
SEDAR
News Releases
42 KB
Sep-26-2023
-
Cardiol Therapeutics Inc. (TSX:CRDL)
SEDAR
News Releases
42 KB
Sep-26-2023
Sep-26-2023
Cardiol Therapeutics Inc. (TSX:CRDL)
SEC
6-K
25 KB
Sep-20-2023
-
Cardiol Therapeutics Inc. (TSX:CRDL)
SEDAR
Material Change Report
306 KB
Sep-20-2023
Sep-20-2023
Cardiol Therapeutics Inc. (TSX:CRDL)
SEC
6-K
31 KB
Sep-19-2023
-
Cardiol Therapeutics Inc. (TSX:CRDL)
SEDAR
News Releases
46 KB
Sep-19-2023
Sep-19-2023
Cardiol Therapeutics Inc. (TSX:CRDL)
SEC
6-K
28 KB
Aug-10-2023
Jun-30-2023
Cardiol Therapeutics Inc. (TSX:CRDL)
SEC
6-K
643 KB
Aug-10-2023
Jun-30-2023
Cardiol Therapeutics Inc. (TSX:CRDL)
SEDAR
Interim Financial Statements
255 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Willner Esq., Michael Jay (Independent Director)
Sep-29-2023
Class A Common Share
20,245
-
Derivative Exercise and Retained Stock
2.70
Multiple
Loxam M.B.A., Teri  (Independent Director)
Jun-06-2023
Class A Common Share
30,000
-
Derivative Exercise and Retained Stock
100.00
Multiple
Hamer M.D., Andrew Warwick (Chief Medical Officer & Head of Research & Development)
Dec-30-2022
Class A Common Share
6,047
-
Derivative Exercise and Retained Stock
6.05
Multiple
Willner Esq., Michael Jay (Independent Director)
Nov-29-2022
Class A Common Share
80,991
-
Derivative Exercise and Retained Stock
12.09
Multiple
Loxam M.B.A., Teri  (Independent Director)
Nov-29-2022
Class A Common Share
30,000
-
Derivative Exercise and Retained Stock
New
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Torre-Amione, Guillermo 
Independent Chairman
-
-

Elsley, David G.
President, CEO & Director
905.491.6793
-
david.elsley@cardiolrx.com
Waddick, Christopher J.
CFO, Corporate Secretary & Director
-
-

Chao, Jennifer M.
Independent Director
-
-

Loxam, Teri 
Independent Director
(212) 821-0110
-

Hill, Joseph A.
Member of Scientific Advisory Board
-
-

McManus, Bruce 
Member of Scientific Advisory Board
-
-

Pekos, Peter 
Independent Director
-
-

Ridker, Paul M.
Member of Scientific Advisory Board
-
-

Stott, Colin G.
Independent Director
-
-

Willner, Michael Jay
Independent Director
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Elsley, David G.
President, CEO & Director
905.491.6793
-
david.elsley@cardiolrx.com
Waddick, Christopher J.
CFO, Corporate Secretary & Director
-
-

Lim, Bernard 
Chief Operating Officer
-
-

Burns, Trevor 
Investor Relations
+1-289-910-0855
-
trevor.burns@cardiolrx.com
Hamer, Andrew Warwick
Chief Medical Officer & Head of Research & Development
-
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
